Cargando…

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

BACKGROUND: Recombinant tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) induces tumour-selective apoptosis in various pre-clinical models by binding its specific receptors expressed on cancer cells. Mapatumumab is a fully human monoclonal antibody that is agonistic to the TRAIL Rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Trarbach, T, Moehler, M, Heinemann, V, Köhne, C-H, Przyborek, M, Schulz, C, Sneller, V, Gallant, G, Kanzler, S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2822942/
https://www.ncbi.nlm.nih.gov/pubmed/20068564
http://dx.doi.org/10.1038/sj.bjc.6605507
_version_ 1782177579389681664
author Trarbach, T
Moehler, M
Heinemann, V
Köhne, C-H
Przyborek, M
Schulz, C
Sneller, V
Gallant, G
Kanzler, S
author_facet Trarbach, T
Moehler, M
Heinemann, V
Köhne, C-H
Przyborek, M
Schulz, C
Sneller, V
Gallant, G
Kanzler, S
author_sort Trarbach, T
collection PubMed
description BACKGROUND: Recombinant tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) induces tumour-selective apoptosis in various pre-clinical models by binding its specific receptors expressed on cancer cells. Mapatumumab is a fully human monoclonal antibody that is agonistic to the TRAIL Receptor 1 (TRAIL-R1). METHODS: This phase II multicentre study was designed to evaluate the efficacy and safety of mapatumumab in patients with colorectal cancer (CRC) who had failed to respond to, were intolerant to, or not candidates for fluoropyrimidine, oxaliplatin, and irinotecan-based regimens. All patients received two loading doses of mapatumumab (20 mg kg(−1) every 14 days), followed by maintenance therapy with 10 mg kg(−1) infused every 14 days. RESULTS: A total of 38 patients, who had progressive disease after a median of three earlier chemotherapy lines, were enrolled. No response according to the Response Evaluation Criteria in Solid Tumors was observed. A total of 12 patients (32%) achieved stable disease for a median of 2.6 months. The median progression-free survival was 1.2 months. The most common adverse events reported, regardless of relationship, were fatigue, nausea, anorexia, and abdominal pain. Plasma mapatumumab concentrations were within the range of exposures predicted by the results of phase I studies of mapatumumab. CONCLUSION: No clinical activity of single-agent mapatumumab was observed in patients with advanced refractory CRC. However, on the basis of its favourable safety profile and pre-clinical evidence of potential synergy in combination with agents commonly used in the treatment of colorectal cancer, further evaluation of mapatumumab in combination with chemotherapy is warranted.
format Text
id pubmed-2822942
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-28229422011-02-02 Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer Trarbach, T Moehler, M Heinemann, V Köhne, C-H Przyborek, M Schulz, C Sneller, V Gallant, G Kanzler, S Br J Cancer Clinical Study BACKGROUND: Recombinant tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) induces tumour-selective apoptosis in various pre-clinical models by binding its specific receptors expressed on cancer cells. Mapatumumab is a fully human monoclonal antibody that is agonistic to the TRAIL Receptor 1 (TRAIL-R1). METHODS: This phase II multicentre study was designed to evaluate the efficacy and safety of mapatumumab in patients with colorectal cancer (CRC) who had failed to respond to, were intolerant to, or not candidates for fluoropyrimidine, oxaliplatin, and irinotecan-based regimens. All patients received two loading doses of mapatumumab (20 mg kg(−1) every 14 days), followed by maintenance therapy with 10 mg kg(−1) infused every 14 days. RESULTS: A total of 38 patients, who had progressive disease after a median of three earlier chemotherapy lines, were enrolled. No response according to the Response Evaluation Criteria in Solid Tumors was observed. A total of 12 patients (32%) achieved stable disease for a median of 2.6 months. The median progression-free survival was 1.2 months. The most common adverse events reported, regardless of relationship, were fatigue, nausea, anorexia, and abdominal pain. Plasma mapatumumab concentrations were within the range of exposures predicted by the results of phase I studies of mapatumumab. CONCLUSION: No clinical activity of single-agent mapatumumab was observed in patients with advanced refractory CRC. However, on the basis of its favourable safety profile and pre-clinical evidence of potential synergy in combination with agents commonly used in the treatment of colorectal cancer, further evaluation of mapatumumab in combination with chemotherapy is warranted. Nature Publishing Group 2010-02-02 2010-01-12 /pmc/articles/PMC2822942/ /pubmed/20068564 http://dx.doi.org/10.1038/sj.bjc.6605507 Text en Copyright © 2010 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical Study
Trarbach, T
Moehler, M
Heinemann, V
Köhne, C-H
Przyborek, M
Schulz, C
Sneller, V
Gallant, G
Kanzler, S
Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
title Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
title_full Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
title_fullStr Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
title_full_unstemmed Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
title_short Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
title_sort phase ii trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (trail-r1), in patients with refractory colorectal cancer
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2822942/
https://www.ncbi.nlm.nih.gov/pubmed/20068564
http://dx.doi.org/10.1038/sj.bjc.6605507
work_keys_str_mv AT trarbacht phaseiitrialofmapatumumabafullyhumanagonisticmonoclonalantibodythattargetsandactivatesthetumournecrosisfactorapoptosisinducingligandreceptor1trailr1inpatientswithrefractorycolorectalcancer
AT moehlerm phaseiitrialofmapatumumabafullyhumanagonisticmonoclonalantibodythattargetsandactivatesthetumournecrosisfactorapoptosisinducingligandreceptor1trailr1inpatientswithrefractorycolorectalcancer
AT heinemannv phaseiitrialofmapatumumabafullyhumanagonisticmonoclonalantibodythattargetsandactivatesthetumournecrosisfactorapoptosisinducingligandreceptor1trailr1inpatientswithrefractorycolorectalcancer
AT kohnech phaseiitrialofmapatumumabafullyhumanagonisticmonoclonalantibodythattargetsandactivatesthetumournecrosisfactorapoptosisinducingligandreceptor1trailr1inpatientswithrefractorycolorectalcancer
AT przyborekm phaseiitrialofmapatumumabafullyhumanagonisticmonoclonalantibodythattargetsandactivatesthetumournecrosisfactorapoptosisinducingligandreceptor1trailr1inpatientswithrefractorycolorectalcancer
AT schulzc phaseiitrialofmapatumumabafullyhumanagonisticmonoclonalantibodythattargetsandactivatesthetumournecrosisfactorapoptosisinducingligandreceptor1trailr1inpatientswithrefractorycolorectalcancer
AT snellerv phaseiitrialofmapatumumabafullyhumanagonisticmonoclonalantibodythattargetsandactivatesthetumournecrosisfactorapoptosisinducingligandreceptor1trailr1inpatientswithrefractorycolorectalcancer
AT gallantg phaseiitrialofmapatumumabafullyhumanagonisticmonoclonalantibodythattargetsandactivatesthetumournecrosisfactorapoptosisinducingligandreceptor1trailr1inpatientswithrefractorycolorectalcancer
AT kanzlers phaseiitrialofmapatumumabafullyhumanagonisticmonoclonalantibodythattargetsandactivatesthetumournecrosisfactorapoptosisinducingligandreceptor1trailr1inpatientswithrefractorycolorectalcancer